Magnetic resonance Imaging - Measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma

Clinical Cancer Research

Volumn 14, Issue 17, 2008, Pages 5548-5554

  De Bazelaire, Cedric ^a   Alsop, David C ^a,d   George, Daniel ^c   Pedrosa, Ivan ^a,d   Wang, Yongyu ^e   Michaelson, M Dror ^b   Rofsky, Neil M ^a,d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE; IOPROMIDE; VATALANIB; ANGIOGENESIS INHIBITOR; PHTHALAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

ADRENAL METASTASIS; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD FLOWMETRY; BONE METASTASIS; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SPIN LABELING; TREATMENT OUTCOME; TUMOR BLOOD FLOW; TUMOR VOLUME; BLOOD FLOW; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; FEASIBILITY STUDY; KIDNEY TUMOR; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHASE 2 CLINICAL TRIAL; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEASIBILITY STUDIES; HUMANS; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PHTHALAZINES; PYRIDINES; REGIONAL BLOOD FLOW;

EID: 53049106264     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0417     Document Type: Article

References (32)

1. Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med 1995;1:120-2.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
3. Drevs J, Hofmann I, Hugenschmidt H, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000;60:4819-24.
4. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-92.
5. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002;20:3906-27.
6. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
7. Drevs J, Muller -Driver R,Wittig C, et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002; 62:4015-22.
8. Anderson SA, Rader RK, Westlin WF, et al. Magnetic resonance contrast enhancement of neovasculature with α(v)h(3)-targeted nanoparticles. Magn Reson Med 2000;44:433-9.
9. Chen X. Multimodality imaging of tumor integrin αvβ3 expression. Mini Rev Med Chem 2006;6: 227-34.
10. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191: 41 -51.
11. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 1998;40:793-9.
12. Morgan B,Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a bio- marker for the pharmacological response of PTK787/ ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21:3955-64.
13. Thomas AL, Morgan B, Horsfield MA, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005;23:4162-71.
14. Sadowski E, Bennett L, Chan M, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148-57.
15. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002; 20:3804-14.
16. Williams DS, Detre JA, Leigh JS, Koretsky AP. Magnetic resonance imaging of perfusion using spin inversion of arterial water. Proc Nat Acad Sci USA 1992; 89:212-6.
17. Alsop DC, Detre JA. Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow. J Cereb Blood Flow Metab 1996; 16:1236-49.
18. Ye FQ, Berman KF, EllmoreT, et al. H215O PET validation of steady-state arterial spin tagging cerebral blood flow measurements in humans. Magn Reson Med 2000;44:450-6.
19. George D, Michaelson D, Oh W, et al. Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2003;22: abstr 1548.
20. De Bazelaire C, Rofsky NM, Duhamel G, Michaelson MD, George D, Alsop DC. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma. Acad Radiol 2005;12:347-57.
21. Ye FQ, Frank JA, Weinberger DR, McLaughlin AC. Noise reduction in 3D perfusion imaging by attenuating the static signal in arterial spin tagging (ASSIST). Magn Reson Med 2000;44:92-100.
22. de Bazelaire CM, Duhamel GD, Rofsky NM, Alsop DC. MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology 2004;230:652-9.
23. Constantinides CD, Atalar E, McVeigh ER. Signal to-noise measurements in magnitude images from NMR phased arrays. Magn Reson Med 1997;38:852-7.
24. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-14.
25. Miller KD, Sweeney CJ, Sledge GW, Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-206.
26. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol 2001;74: 983-6.
27. Brasch R, Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolec- ular contrast media: status report. Eur J Radiol 2000; 34:148-55.
28. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998;95:8795-800.
29. Boehm T, Folkman J, Browder T, O'Reilly MS. Anti- angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390: 404-7.
30. Kerbel RS,Yu J,Tran J, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001;20:79-86.
31. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001;19:851 -6.
32. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast- enhanced magnetic resonance imaging as a pharma- codynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005;23:5464-73.